Genetic heterogeneity of HER2 in breast cancer: Impact on HER2 testing and its clinicopathologic significance

Breast Cancer Research and Treatment

Volumn 134, Issue 3, 2012, Pages 1095-1102

  Yang, Yi Ling ^a   Fan, Yu ^a   Lang, Rong Gang ^a   Gu, Feng ^a   Ren, Mei Jing ^a   Zhang, Xin Min ^b   Yin, Dong ^a   Fu, Li ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

American society of clinical oncology college of American pathologists guideline; Breast carcinoma; Clinicopathologic characteristic; Genetic heterogeneity; HER2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PARAFFIN;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; YOUNG ADULT;

EID: 84868207560     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2046-0     Document Type: Article

References (38)

1. Gutierrez C, Schiff R (2011) HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135(1):55-62
2. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A et al (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15(8):2894-2904
3. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R et al (1993) Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53(20):4960-4970
4. Yamauchi H, Stearns V, Hayes DF (2001) When is a tumor marker ready for prime time? a case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19(8):2334-2356
5. Menard S, Valagussa P, Pilotti S, Gianni L, Biganzoli E, Boracchi P, Tomasic G, Casalini P, Marubini E, Colnaghi MI et al (2001) Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 19(2):329-335
6. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719-726
7. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354(8):809-820
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659-1672
9. Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA (2007) Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 110(3):489-498
10. Chargari C, Kirov KM, Bollet MA, Magne N, Vedrine L, Cremades S, Beuzeboc P, Fourquet A, Kirova YM (2011) Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment. Cancer Treat Rev 37(4):321-330
11. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118-145
12. Cottu PH, Asselah J, Lae M, Pierga JY, Dieras V, Mignot L, Sigal-Zafrani B, Vincent-Salomon A (2008) Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 19(3):595-597
13. Wu JM, Halushka MK, Argani P (2010) Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol 41(6):914-917
14. Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW (2005) Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 124(2):273-281
15. Chivukula M, Bhargava R, Brufsky A, Surti U, Dabbs DJ (2008) Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. Mod Pathol 21(4):363-368
16. Brunelli M, Manfrin E, Martignoni G, Miller K, Remo A, Reghellin D, Bersani S, Gobbo S, Eccher A, Chilosi M et al (2009) Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 131(5):678-682
17. Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB, Persons DL, Tubbs RR, Hammond ME (2009) Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 133(4):611-612
18. Tavassoli FA, Devilee P (2003) Pathology and genetics of tumours of the breast and female genital organs. World Health Organization, France
19. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784-2795
20. Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J et al (2009) Outcome of patients with early-stage breast cancer treated with doxorubicinbased adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 27(24):3881-3886
21. Park SY, Gonen M, Kim HJ, Michor F, Polyak K (2010) Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 120(2):636-644
22. Li Z, Jin K, Lan H, Teng L (2011) Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure? Hepatogastroenterology 58(106):411-416
23. Bernasconi B, Chiaravalli AM, Finzi G, Milani K, Tibiletti MG (2011) Genetic heterogeneity in HER2 testing may influence therapy eligibility. Breast cancer research and treatment
24. Zarbo RJ, Hammond ME (2003) Conference summary, strategic science symposium. Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med 127(5):549-553
25. Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Denoux Y, Fiche M, Jacquemier J, Mathieu MC, Penault-Llorca F, Rigaud C et al (2003) Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 42(4):337-347
26. Pertschuk LP, Axiotis CA, Feldman JG, Kim YD, Karavattayhayyil SJ, Braithwaite L (1999) Marked intratumoral heterogeneity of the proto-oncogene her-2/neu determined by three different detection systems. Breast J 5(6):369-374
27. Ohlschlegel C, Zahel K, Kradolfer D, Hell M, Jochum W (2011) HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol 64(12):1112-1116
28. Shin SJ, Hyjek E, Early E, Knowles DM (2006) Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in situ hybridization and tissue microarray. Int J Surg Pathol 14(4):279-284
29. Glockner S, Buurman H, Kleeberger W, Lehmann U, Kreipe H (2002) Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 82(10):1419-1426
30. Hanna W, Nofech-Mozes S, Kahn HJ (2007) Intratumoral heterogeneity of HER2/neu in breast cancer-a rare event. Breast J 13(2):122-129
31. Andersson J, Linderholm B, Bergh J, Elmberger G (2004) HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl Immunohistochem Mol Morphol 12(1):14-20
32. Chibon F, De Mascarel I, Sierankowski G, Brouste V, Bonnefoi H, Debled M, Mauriac L, MacGrogan G (2009) Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations. Mod Pathol 22(3):403-409
33. Zeng X, Liang ZY, Wu SF, Zhou WX, Gao J, Liu TH (2006) Analysis of HER2 gene status in breast cancer with HER2 protein overexpression. Zhonghua Bing Li Xue Za Zhi 35(10):584-588
34. Zeng X, Zhao DC, Zhou WX, Wu SF, Liang ZY, Liu TH (2005) Evaluation of HER2 gene expression status in breast cancer by fluorescence in situ hybridization. Zhonghua Bing Li Xue Za Zhi 34(11):701-705
35. Nunes CB, Rocha RM, Reis-Filho JS, Lambros MB, Rocha GF, Sanches FS, Oliveira FN, Gobbi H (2008) Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J Clin Pathol 61(8):934-938
36. Bartlett J, Mallon E, Cooke T (2003) The clinical evaluation of HER-2 status: which test to use? J Pathol 199(4):411-417
37. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14(4):320-368
38. Perez EA (2008) Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin breast cancer 8(Suppl 3):S114-S120